hotspot -WSS

hotspot

author：knowledge 2025-09-27 19:50:20 - browse：2957

Obesity conference attendees with a pink and blue Wegovy sign hanging from the ceiling above. -- obesity coverage from STAT — Wegovy, the obesity drug, was inescapable at the ObesityWeek conference in Dallas. Elaine Chen

DALLAS — Here at ObesityWeek, one of the largest conferences on obesity, Novo Nordisk and Eli Lilly are displaying more than a dozen studies that together carry the message: Our blockbuster weight loss treatments will be worth it for society.

But experts point out that much of this company-funded research does not include the cost of the drugs themselves, which sell at more than $10,000 per year in the U.S. and are meant to be taken indefinitely.

The two major pharmaceutical companies have seen interest skyrocket for their GLP-1-based drugs like Ozempic, Wegovy, and Mounjaro, a new generation of medications that can cut substantial amounts of weight. But insurance plans have been slow to grant wide access to obesity treatments, concerned that the vast amount of people eligible to take them, along with their high price, could lead to significant financial strain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： An inside look at PIPEs, biotech's buzzy new financing tool

explore

WSS

Obesity now affects over 1 billion people worldwide, study finds

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

How to address the problem of discarded donor organs

Biotech companies concerned about China biosecurity crackdown

Senate panel to vote on hospitals, PBMs, prisoner care

Telehealth options flood the market as retailers push virtual care

Wikipedia

hotspot

focus

Tori Bowie and the unacceptable rates of Black maternal death

Testing for cancer recurrence creates a new limbo for patients

23andMe had bad news about my health. I wish a person had delivered it

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Trump demands the U.S. pay no more for drugs than other countries … again

Testing for cancer recurrence creates a new limbo for patients

Activists slam private health insurers over coverage restrictions

Congress gives doctors Medicare pay bump

Trump demands the U.S. pay no more for drugs than other countries … again

Biden's order seeks to regulate AI risk without stifling innovation

explore

Flu vaccine offering decent levels of protection this winter, new data show

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Readout Newsletter: What happened with Sarepta's Duchenne data

Biden's order seeks to regulate AI risk without stifling innovation

International team creates first chimeric human

An inside look at PIPEs, biotech's buzzy new financing tool

entertainment

explore

explore

hotspot